Issa Mohamad’s Post

Leading experts offer insights into colorectal cancer, including its prevalence, staging, and the current landscape of treatment options. MD Anderson Cancer Center https://lnkd.in/es43dZ5F #crcsm #cancer #Oncology

The main potential benefit of screening is saving lives from cancer: Screening can help to detect cancer at an early stage. Learn more about breast cancer screening with Busamed. #Busamed #BreastCancerAwareness

**Revolutionizing Cancer Treatment: Incredible Video Shows T-cells in Action** New video captures the fascinating moment when T-cells target and fight cancer cells, leading to improved treatment strategies. Have you ever seen T-cells in action? This groundbreaking video will change the way you think about cancer treatment. ⚡️ #cancerawareness, #tcells, #cancertreatment, #cartherapy, #medicalinnovation

Check out this article in TIME where our CSO of Oncology R&D Jeffrey Settleman delves into our legacy in precision medicine and vision for the future, where every person living with cancer has access to biomarker-driven treatment options that are right for their type of cancer. #PFEColleague

 🟣 Connecting the dots 🟣 Read more about development in the world of cancer therapy development and how this link to our program. For instance, read about the importance of a patient-centric approach, which is something that Oncode Accelerator is implementing in its program. For the whole article click the link below 👇

#ICYMI: Eric Miller, MD, PhD, of OSU Comprehensive Cancer Center, leads Alliance A022101/ERASur, a trial for patients with metastatic #colorectalcancer that compares total ablative therapy and usual systemic therapy to usual systemic therapy alone. To learn more about the ERASur trial, visit https://lnkd.in/gQus2pDQ #NCI #NCTN Fight Colorectal Cancer

In this #AJMCInsights series, experts examine primary and acquired resistance mechanisms in immunotherapy, while offering realistic treatment strategies for patients with non–small cell lung cancer. Watch the videos: https://bit.ly/3xtKNRq #LungCancer

📑Today we share the #Review "Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer" ✍by Shenduo Li et al. Mayo Clinic Access the full paper here▶️ https://lnkd.in/d4FzAuse Keywords: NSCLC; targeted therapy; phase I/II

For #TrialTuesday, Haeseong Park, MD, PhD, of Dana-Farber Cancer Institute, lead the Alliance A022102 trial that compares the effect of mFOLFIRINOX versus mFOLFOX with or without nivolumab to treat patients with #metastatic HER2 negative #gastroesophageal cancer. To learn more about this trial, visit https://lnkd.in/g3jFJnRR #NCI #NCTN #gastriccancer

Check out this article in TIME where our CSO of Oncology R&D Jeffrey Settleman delves into our legacy in precision medicine and vision for the future, where every person living with cancer has access to biomarker-driven treatment options that are right for their type of cancer. #PFEColleague